Last reviewed · How we verify
NCT04862273: CMR for CA
CMR T1 Mapping for Diagnosis of Cardiac Amyloidosis
trial testing Native T1 CMR in Heart Failure NYHA Class II in 112 participants. Completed in 1 December 2024.
1 March 2023
Quick facts
| Lead sponsor | University of Leipzig |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 112 |
| Start date | 1 April 2021 |
| Primary completion | 1 March 2023 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Native T1 CMR
- Web-based ATTR probability estimator (Pfizer, New York)
- 99mTc-DPD scintigraphy
- Laboratory screening for multiple myeloma / AL amyloidosis
- Cardiac biopsy
Conditions studied
- Heart Failure NYHA Class II — all drugs for Heart Failure NYHA Class II →
- Heart Failure NYHA Class III — all drugs for Heart Failure NYHA Class III →
- Heart Failure NYHA Class IV — all drugs for Heart Failure NYHA Class IV →
- Heart Failure With Preserved Ejection Fraction — all drugs for Heart Failure With Preserved Ejection Fraction →
Sponsor
University of Leipzig
Who can join
60 and older, any sex, with Heart Failure NYHA Class II or Heart Failure NYHA Class III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to test the diagnostic accuracy of T1 mapping for the diagnosis of cardiac amyloidosis prospectively. The hypothesis is that T1 mapping in older patients with symptomatic heart failure, increased LV wall thickness and elevated cardiac biomarkers is non-inferior to the reference method to diagnose cardiac amyloidosis (CA). As secondary measure, a web-based ATTR probability estimator for the diagnosis of CA will be evaluated.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Native T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy.
Lavall D, Vosshage NH, Geßner R, Stöbe S, et al · · 2023 · cited 10× · PMID 35355115 · DOI 10.1007/s00392-022-02005-2
Verify or expand the search:
- PubMed search for NCT04862273
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure NYHA Class II
Currently open trials in the same condition.
- NCT05632432 — Atrial Appendage Micrograft Transplants to Assist Heart Repair After Cardiac Surgery · NA · recruiting
- NCT04829617 — Promoting Well-being and Health in Heart Failure · NA · recruiting
- NCT03180320 — Baduanjin-eight-silken-movement With Self-efficacy Building for Patients With Chronic Heart Failure (BESMILE-HF Study) · NA · recruiting
Other University of Leipzig trials
Trials by the same sponsor.
- NCT07155564 — Validation of Energy Expenditure Measures Study · recruiting
- NCT06656832 — Peripheral Drivers of Heart Failure Progression - the Prospective PEDAL-HF Study · NA · not yet recruiting
- NCT06526013 — Cholesterol Self-testing in Patients Post Acute Coronary Syndrome · NA · recruiting
- NCT06420622 — INDIcators for Clarifying the bAckground of exTreme Obesity in childRen · recruiting
- NCT06269263 — Feasibility of Home-based Cardiac Rehabilitation in Patients With Chronic Heart Failure (Pilot-CRHF) · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04862273 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Leipzig
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04862273.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing